Johnson & Johnson (JNJ) Non-Current Deferred Tax Liability (2009 - 2026)

Johnson & Johnson (JNJ) posted Non-Current Deferred Tax Liability of $7.0 billion for Q1 2026, up 3.24% sequentially from $6.8 billion in Q4 2025, and up 188.76% YoY from $2.4 billion in Q1 2025.

Johnson & Johnson (JNJ) Non-Current Deferred Tax Liability (2009 - 2026) Analysis & Trends

Johnson & Johnson (JNJ) has 18 years of Non-Current Deferred Tax Liability data on file, last reported at $7.0 billion in Q1 2026.

  • Quarterly Non-Current Deferred Tax Liability rose 188.76% year-over-year to $7.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.0 billion (up 188.76% YoY) and the FY2025 annual result came in at $6.8 billion, up 177.41% from the prior year.
  • Non-Current Deferred Tax Liability improved to $7.0 billion in Q1 2026 per JNJ's latest filing, from $6.8 billion in the prior quarter.
  • The five-year high for Non-Current Deferred Tax Liability was $7.5 billion in Q1 2022, with the low at $2.4 billion in Q1 2025.
  • Average Non-Current Deferred Tax Liability over 5 years is $4.4 billion, with a median of $3.9 billion recorded in 2023.
  • Year-over-year, Non-Current Deferred Tax Liability slumped 46.97% in 2023 and jumped 188.76% in 2026.
  • Johnson & Johnson's Non-Current Deferred Tax Liability stood at $4.9 billion in 2022, then slumped by 35.44% to $3.2 billion in 2023, then dropped by 23.33% to $2.4 billion in 2024, then surged by 177.41% to $6.8 billion in 2025, then climbed by 3.24% to $7.0 billion in 2026.
  • Business Quant data shows JNJ's Non-Current Deferred Tax Liability at $7.0 billion in Q1 2026, $6.8 billion in Q4 2025, and $6.0 billion in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn

Historic Data

Download Data
DateValue
Mar 29, 2026 7.01 Bn
Mar 29, 2026 7.01 Bn
Dec 28, 2025 6.79 Bn
Dec 28, 2025 6.79 Bn
Sep 28, 2025 5.99 Bn
Sep 28, 2025 5.99 Bn
Jun 29, 2025 3.80 Bn
Jun 29, 2025 3.80 Bn
Mar 30, 2025 2.43 Bn
Mar 30, 2025 2.43 Bn
Dec 29, 2024 2.45 Bn
Dec 29, 2024 2.45 Bn
Sep 29, 2024 2.95 Bn
Sep 29, 2024 2.95 Bn
Jun 30, 2024 2.64 Bn
Jun 30, 2024 2.64 Bn
Mar 31, 2024 3.17 Bn
Mar 31, 2024 3.17 Bn
Dec 31, 2023 3.19 Bn
Dec 31, 2023 3.19 Bn